Western Wealth Management LLC Trims Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Western Wealth Management LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 82.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 829 shares of the medical research company's stock after selling 3,814 shares during the quarter. Western Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $431,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $28,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Noble Wealth Management PBC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $35,000. Finally, Cassady Schiller Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after purchasing an additional 33 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,075 shares of company stock worth $7,305,942. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $1.00 during midday trading on Thursday, reaching $403.13. 1,061,739 shares of the company's stock traded hands, compared to its average volume of 1,871,643. The stock has a 50 day moving average of $435.42 and a 200 day moving average of $502.00. The company has a market cap of $152.18 billion, a price-to-earnings ratio of 24.39, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.11 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TMO shares. Raymond James restated an "outperform" rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Argus dropped their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Finally, Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.